Morgan Stanley Maintains Equal-Weight on Evelo Biosciences, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Evelo Biosciences (NASDAQ:EVLO) and raises the price target from $2 to $10.
July 26, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Evelo Biosciences and raises the price target from $2 to $10.
The raised price target from Morgan Stanley indicates a positive outlook for Evelo Biosciences. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100